✦ LIBER ✦

Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis

✍ Scribed by Bezares, Raimundo Fernando; Stemelin, German; Diaz, Alicia; Argentieri, Daniel; Zubiaur, Emilio Lanari; Garay, Guy; Bartomioli, Miguel; Ryser, Ricardo; Milone, Gustavo

Book ID: 120355705
Publisher: Informa plc
Year: 2011
Tongue: English
Weight: 287 KB
Volume: 52
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2011.584991

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open-label, pilot study of fludarabin

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

✍ Montillo, M.; Tedeschi, A.; Petrizzi, V. B.; Ricci, F.; Crugnola, M.; Spriano, M 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 147 KB

5.44 Consolidation Therapy with Subcutan

5.44 Consolidation Therapy with Subcutaneous Alemtuzumab after Induction Treatment with Oral Fludarabine and Cyclophosphamide in Previously Untreated Patients Aged 65-70 years with Advanced Stage CLL: Final Results of a Phase II Study from the French Cooperative Group on Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia (FCG-CLL/WM)

✍ Alain Delmer; Olivier Tournilhac; Stéphane Leprêtre; Bruno Cazin; Pierre Feugier 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 113 KB